Search | Clinical Trials Finder

Conditions: Dermatomyositis
Interventions: Octagam 10%, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Huntington Beach, California • Los Angeles, California • Orange, California + 14 more

Conditions: Inflammation In Skeletal Muscle
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
Interventions: Imvotamab; Drug
Lead sponsor: IGM Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD5492; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more

Conditions: Myositis
Interventions: Belimumab, Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions: Allogeneic NK Cells; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Buffalo, New York

Conditions: SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Interventions: CTX112; Biological
Lead sponsor: CRISPR Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 9
States / cities: La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more

Conditions: Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions: Gamma Globulin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Inflammatory Myopathies
Interventions: Rapcabtagene autoleucel, Active Comparator Option; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more

Conditions: Dermatomyositis, Polymyositis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 16 Years and older
Enrollment: 1,325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Myositis
Interventions: PF-06823859, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 47
States / cities: Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more

Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions: ALLO-329, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 11 more

Conditions: Autoimmune/Connective Tissue Diseases, Idiopathic Inflammatory Myopathies, Polymyositis, Dermatomyositis
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 2 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions: EFG PH20 SC, PBO; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more

Conditions: Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
Interventions: Diet-Induced Weight Loss, Aerobic Exercise Training; Behavioral
Lead sponsor: Miami University; Other
Eligibility: 58 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Oxford, Ohio

Conditions: Dermatomyositis
Interventions: Abatacept; Drug
Lead sponsor: George Washington University; Other
Eligibility: 7 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sporadic, Inclusion Body, Myositis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 25 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Myositis
Interventions: Nipocalimab, Placebo, Glucocorticoids; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more

Conditions: Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
Interventions: 11C-MC1, Celecoxib, [11C]ER176, Positron Emission Tomography (PET)/computed tomography (CT) Scan; Drug · Diagnostic Test
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions: KYV-101, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: David Porter; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Polymyositis, Dermatomyositis
Interventions: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label); Combination Product · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more

Search by objective public record fields.

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Natural History of Inflammatory Muscle Diseases

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

A Study of AZD0120 in Autoimmune Diseases

Belimumab in Idiopathic Inflammatory Myositis

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Study and Treatment of Inflammatory Muscle Diseases

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older Adults

Abatacept in Juvenile Dermatomyositis

Immune Abnormalities in Sporadic Inclusion Body Myositis

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)